Package Leaflet: Information for the User
REKOVELLE 36micrograms/1.08ml
injectable solution in pre-filled pen
folitropin delta
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
REKOVELLE contains folitropin delta, a follicle-stimulating hormone that belongs to the family of hormones called gonadotropins. Gonadotropins are involved in reproduction and fertility.
REKOVELLE is used to treat female infertility and in women undergoing assisted reproduction techniques such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). REKOVELLE stimulates the ovaries to grow and develop multiple sacs (‘follicles’), from which eggs are obtained that are fertilized in the laboratory.
Before starting treatment with this medicine, a doctor must evaluate you and your partner to examine the possible causes of the infertility problem.
Do not use REKOVELLE
Warnings and precautions
Consult your doctor before using REKOVELLE
Ovarian Hyperstimulation Syndrome
Gonadotropins, such as this medicine, can cause Ovarian Hyperstimulation Syndrome. This occurs when your follicles develop excessively and become large cysts.
Consult your doctor if:
Your doctor may ask you to interrupt treatment with this medicine (see section 4).
If you follow the recommended dose and administration schedule, it is less likely that Ovarian Hyperstimulation Syndrome will occur.
Blood Clotting Problems (Thromboembolic Events)
The formation of blood clots in blood vessels (veins or arteries) is more likely in pregnant women. Infertility treatments can increase the risk of this happening, especially if you are overweight or you or a family member have a known blood clotting problem (thrombophilia). Consult your doctor if you think this applies to you.
Ovarian Torsion
There have been reports of ovarian torsion after assisted reproduction treatment. Ovarian torsion can cut off the blood flow to the ovaries.
Multiple Pregnancy and Birth Defects
When undergoing assisted reproduction treatment, the likelihood of having a multiple pregnancy (such as twins) is mainly related to the number of embryos transferred to your uterus, the quality of the embryos, and your age. Multiple pregnancy can lead to medical complications for you and your babies. Additionally, the risk of birth defects may be slightly higher when undergoing infertility treatment, which is thought to be due to the characteristics of the parents (such as age and sperm characteristics) and multiple pregnancy.
Pregnancy Loss
When undergoing assisted reproduction treatment, it is more likely that you will experience a miscarriage than with natural conception.
Ectopic Pregnancy
When undergoing assisted reproduction treatment, it is more likely that you will have an ectopic pregnancy than with natural conception. If you have a history of tubal disease, the risk of ectopic pregnancy is increased in your case.
Ovarian Tumors and Other Reproductive System Tumors
There have been reports of ovarian tumors and other reproductive system tumors in women who have undergone infertility treatment. It is not known whether treatment with fertility medicines increases the risk of these tumors in infertile women.
Other Medical Conditions
Before starting treatment with this medicine, tell your doctor if:
Children and Adolescents (under 18 years of age)
This medicine is not intended for use in children and adolescents.
Other Medicines and REKOVELLE
Tell your doctor if you are using, have recently used, or might use any other medicines.
Pregnancy and Breast-feeding
Do not use this medicine if you are pregnant or breast-feeding.
Driving and Using Machines
This medicine does not affect your ability to drive or use machines.
REKOVELLE contains sodium
This medicine contains less than 1 mmol of sodium chloride (23 mg) per dose, which is essentially ‘sodium-free’.
Follow the instructions for administration of this medicine exactly as prescribed by your doctor.
In case of doubt, consult your doctor or pharmacist again.
The dose of REKOVELLE for the first treatment cycle will be calculated by your doctor using the level of anti-Müllerian hormone (AMH - a marker of how your ovaries will respond to stimulation with gonadotropins) in your blood and your body weight. Therefore, before starting treatment, the result of the AMH from a blood sample (taken in the last 12 months) must be available. Your body weight will also be measured before starting treatment. The dose of REKOVELLE is expressed in micrograms.
The dose of REKOVELLE is fixed throughout the treatment period, without adjustments to increase or decrease the daily dose. Your doctor will monitor the effect of treatment with REKOVELLE, and treatment will be discontinued when an adequate number of follicles have developed. In general, you will be given a single injection of a medicine called human chorionic gonadotropin (hCG) with a dose of 250 micrograms or 5,000 IU for the final development of the follicles.
If your body responds very weakly or very strongly to treatment, your doctor may decide to discontinue treatment with REKOVELLE. For the next treatment cycle, your doctor may give you a higher or lower daily dose of REKOVELLE than before.
How to administer the injections
The instructions for use of the pre-filled pen must be followed carefully. Do not use the pre-filled pen if the solution contains particles or does not appear clear.
The first injection of this medicine must be administered under the supervision of a doctor or nurse. Your doctor will decide if you can self-administer this medicine at home, but only after you have received adequate training.
This medicine is intended for subcutaneous injection, usually in the abdomen. The pre-filled pen can be used for multiple injections.
If you use more REKOVELLE than you should
The effects of using too much medicine are not known. It is possible that Ovarian Hyperstimulation Syndrome (OHSS) may occur, which is described in section 4.
If you forget to use REKOVELLE
Do not administer a double dose to make up for forgotten doses. Please contact your doctor or pharmacist as soon as you realize you have forgotten a dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects:
The hormones used in infertility treatment, such as this medicine, can cause high levels of activity in the ovaries (Ovarian Hyperstimulation Syndrome). Symptoms can include pain, discomfort, and swelling in the abdomen, nausea, vomiting, diarrhea, weight gain, or difficulty breathing. If you experience any of these symptoms, please contact your doctor immediately.
The risk of side effects is classified into the following categories:
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label of the pre-filled pen and the carton after ‘EXP’. The expiry date is the last day of the month stated.
Store in a refrigerator (2°C - 8°C). Do not freeze.
Keep the pre-filled pen in the original package to protect it from light.
REKOVELLE can be stored at or below 25°C for up to 3 months, including the period after the first use. It must not be refrigerated again and must be discarded if not used after 3 months.
After the first use: 28 days when stored at or below 25°C.
At the end of the treatment, the unused product must be discarded.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of REKOVELLE
Each pre-filled pen with a multi-dose cartridge contains 36 micrograms of folitropin delta in 1.08 milliliters of solution. One milliliter of solution contains 33.3 micrograms of folitropin delta per milliliter of solution.
Appearance of the Product and Container Contents.
REKOVELLE is a clear and colorless solution for injection in a pre-filled pen. It is available in packs of 1 pre-filled pen and 9 needles.
Marketing Authorization Holder
Ferring Pharmaceuticals A/S
Amager Strandvej 405
2770 Kastrup
Denmark
Manufacturer
Ferring GmbH
Wittland 11
D-24109 Kiel
Germany
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien Ferring N.V. Tel/Tél: +32 53 72 92 00 ferringnvsa@ferring.be | Lithuania CentralPharma Communications UAB Tel: +370 5 243 0444 centralpharma@centralpharma.lt |
Bulgaria Farmont Ltd. Tel: +359 2 807 5022 farmont@farmont.bg | Luxembourg/Luxemburg Ferring N.V. Belgique/Belgien Tel/Tél: +32 53 72 92 00 ferringnvsa@ferring.be |
Czech Republic Ferring Pharmaceuticals CZ s.r.o. Tel: +420 234 701 333 cz1-info@ferring.com | Hungary Ferring Magyarország Gyógyszerkereskedelmi Kft. Tel: +36 1 236 3800 ferring@ferring.hu |
Denmark Ferring Lægemidler A/S Tlf: +45 88 16 88 17 | Malta E.J. Busuttil Ltd. Tel: +356 21447184 info@ejbusuttil.com |
Germany Ferring Arzneimittel GmbH Tel: +49 431 5852 0 info-service@ferring.de | Netherlands Ferring B.V. Tel: +31 235680300 infoNL@ferring.com |
Estonia CentralPharma Communications OÜ Tel: +372 601 5540 centralpharma@centralpharma.ee | Norway Ferring Legemidler AS Tlf: +47 22 02 08 80 mail@oslo.ferring.com |
Greece Ferring Ελλάς ΜΕΠΕ Τηλ: +30 210 68 43 449 | Austria Ferring Arzneimittel Ges.m.b.H Tel: +43 1 60 8080 office@ferring.at |
Spain Ferring S.A.U. Tel: +34 91 387 70 00 Registros@ferring.com | Poland Ferring Pharmaceuticals Poland Sp. z o.o. Tel: +48 22 246 06 80 PL0-Recepcja@ferring.com |
France Ferring S.A.S. Tél: +33 1 49 08 67 60 information.medicale@ferring.com | Portugal Ferring Portuguesa – Produtos Farmacêuticos, Sociedade Unipessoal, Lda. Tel: +351 21 940 51 90 |
Croatia Clinres farmacija d.o.o. Tel: +385 1 2396 900 info@clinres-farmacija.hr | Romania Ferring Pharmaceuticals Romania SRL Tel: +40 356 113 270 |
Ireland Ferring Ireland Ltd. Tel: +353 1 4637355 EnquiriesIrelandMailbox@ferring.com | Slovenia SALUS, Veletrgovina, d.o.o. Tel: +386 1 5899 100 regulatory@salus.si |
Iceland Vistor hf. Sími: +354 535 70 00 | Slovakia Ferring Slovakia s.r.o. Tel: +421 2 54 416 010 SK0-Recepcia@ferring.com |
Italy Ferring S.p.A. Tel: +39 02 640 00 11 | Finland Ferring Lääkkeet Oy Puh/Tel: +358 207 401 440 info@ferring.fi |
Cyprus A.Potamitis Medicare Ltd Τηλ: +357 22583333 a.potamitismedicare@cytanet.com.cy | Sweden Ferring Läkemedel AB Tel: +46 40 691 69 00 info@ferring.se |
Latvia CentralPharma Communications SIA Talr: +371 674 50497 centralpharma@centralpharma.lv | United Kingdom(Northern Ireland) Ferring Ireland Ltd Tel: +353 1 4637355 EnquiriesIrelandMailbox@ferring.com |
Date of Last Revision of this Leaflet.
Detailed and up-to-date information on this medicine is available on the European Medicines Agency (EMA) website: http://www.ema.europa.eu.
Instructions for Use
REKOVELLE Pre-filled Pen
folitropin delta
Your healthcare professional should teach you how to properly prepare and inject REKOVELLE before you inject it for the first time.
Do not attempt to inject it yourself until you have been trained by your healthcare professional in the correct way to administer the injections.
Read this entire manual before using the REKOVELLE pre-filled pen and each time you acquire a new pen. There may be new information. Follow these instructions carefully, even if you have used a similar injectable pen before. Incorrect use of the pen may result in an incorrect dose of the medicine.
Contact your healthcare professional (doctor, nurse, or pharmacist) if you have any questions about how to administer your REKOVELLE injection.
The REKOVELLE pre-filled pen is a disposable, dosing pen that can be used for the administration of more than 1 dose of REKOVELLE. The pen is available in 3 different concentrations:
REKOVELLE Pre-filled Pen and its Parts
Instructions for Use – REKOVELLE Pre-filled Pen (folitropin delta)
Important Information
Information about your REKOVELLE Pre-filled Pen
The pen can be set for the administration of doses from 0.33 micrograms to 20 micrograms of REKOVELLE in marked increments of 0.33 micrograms. See “Examples of how to set a dose” on pages 20 to 211.
Cleaning
Storage
Before Use:
After First Use (Usage Period):
Items You Will Need to Administer Your REKOVELLE Injection
Before Use – (Step 1)
Step 1:
Attaching the Needle – (Steps 2 to 6)
Important:
Step 2:
Step 3:
Step 4:
Step 5:
Step 6:
Preparation – (Steps 7 to 9)
Step 7:
Step 8:
Step 9:
(If you still do not see a drop after using a new needle, try with a new pen.)
Setting the Dose – (Step 10)
See “Examples of how to set a dose” on pages 20 to 211.
Step 10:
Dose Division:
See “Administering a Divided Dose of REKOVELLE” on pages 22 to 231 for examples of how to calculate and record your divided dose.
Injecting the Dose – (Steps 11 to 12)
Important:
Steps 11 and 12:
Note:
Disposing of the Needle – (Step 13)
Step 13:
Note:
Replacing the Cap on the Pen – (Step 14)
Step 14:
Note:
Disposal
Needles:
Place used needles in a sharps container, such as a container for sharp objects, immediately after use. Do not discard the used container with your household waste.
If you do not have a sharps container, you can use a household container that has the following characteristics:
Following characteristics:
REKOVELLE pre-filled pens:
Examples of how to dial a dose
Examples of how to dial a dose using your REKOVELLE pre-filled pen
The following table shows examples of prescribed doses, how to dial the examples of prescribed doses, and what the dose display window looks like for the prescribed doses.
Examples of prescribed doses (in micrograms) | Dose to be dialed on the pen | Dose display window for the examples of prescribed dose |
0.33 | 0 and 1 line (dial up to 0 plus 1 click) | |
0.66 (preparation dose) | 0 and 2 lines (dial up to 0 plus 2 clicks) | |
2.33 | 2 and 1 line (dial up to 2 plus 1 click) | |
11.00 | 11 (dial up to 11) | |
12.33 | 12 and 1 line (dial up to 12 plus 1 click) | |
18.66 | 18 and 2 lines (dial up to 18 plus 2 clicks) | |
20.00 | 20 (dial up to 20) |
Administration of a split dose of REKOVELLE
If you are unable to dial the complete prescribed dose on your pen, this means that there is not enough medication left in the pen to administer the complete dose. You will need to administer part of your prescribed dose using the pen you are using, and the rest of the dose using a new pen (split dose injection) or you will need to discard the pen you are using and use a new pen to administer the complete prescribed dose in a single injection. If you decide to administer the split dose in two injections, follow these instructions and write down the amount of medication to be administered using the split dose diary on page 231.
Split dose diary
Frequently asked questions
Precautions
Additional information
Needles
Needles are provided with the pen. If you need additional needles, contact your healthcare professional. Use only the needles that come with the REKOVELLE pre-filled pen or the needles that your healthcare professional prescribes for you.
Contact
If you have any questions or problems related to the pen, contact your healthcare professional or local representative of the marketing authorization holder (see the package leaflet for contact information).